Last €0.63 EUR
Change Today -0.011 / -1.73%
Volume 0.0
R3X On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 7:22 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (R3X) Snapshot

Open
€0.65
Previous Close
€0.64
Day High
€0.65
Day Low
€0.63
52 Week High
03/5/14 - €1.16
52 Week Low
07/21/14 - €0.47
Market Cap
111.4M
Average Volume 10 Days
6.9K
EPS TTM
--
Shares Outstanding
178.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REXAHN PHARMACEUTICALS INC (R3X)

Related News

No related news articles were found.

rexahn pharmaceuticals inc (R3X) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (R3X) Details

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.

16 Employees
Last Reported Date: 03/21/14

rexahn pharmaceuticals inc (R3X) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $380.8K
President and Chief Operating Officer
Total Annual Compensation: $268.8K
Founder, Chairman of the Board and Chief Scie...
Total Annual Compensation: $319.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.1K
Compensation as of Fiscal Year 2013.

rexahn pharmaceuticals inc (R3X) Key Developments

Rexahn Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Rexahn Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Rexahn Pharmaceuticals, Inc. Names Richard Rodgers to the Board of Directors

Rexahn Pharmaceuticals, Inc. announced the appointment of Richard Rodgers to the company's Board of Directors. Mr. Rodgers was most recently Executive Vice President, Chief Financial Officer, Secretary and Treasurer of TESARO, which he co-founded, from March 2010 until August 2013. He previously served as the Chief Financial Officer from June 2009 to February 2010 of Abraxis BioScience. Prior to that, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, from 2004 until its acquisition by Eisai, in January 2008. Mr. Rodgers also serves as a director for Ardelyx, Inc.

Rexahn Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 09:00 AM

Rexahn Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 09:00 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Peter D. Suzdak, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
R3X:GR €0.63 EUR -0.011

R3X Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for R3X.
View Industry Companies
 

Industry Analysis

R3X

Industry Average

Valuation R3X Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit www.rexahn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.